Treatment of moderate persistent asthma using inhalation corticosteroids in combination with long-acting β2-adrenergic agonists (bronchodilators) or with leukotriene receptor antagonists (anti-inflammatory agents); the 'step-3-dilemma';Behandeling van matig, persisterend astma: Inhalatiecorticosteroïden combineren met langwerkende β2-adrenerge agonisten (luchtwegverwijders) dan wel met leukotrieenreceptorantagonisten (ontstekingsremmers); het 'stap-3-dilemma'

Nederlands Tijdschrift voor Geneeskunde

Volumn 147, Issue 35, 2003, Pages 1681-1685

  Diamant, Z ^a   Dekhuijzen, P N R ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; GLUCOCORTICOID; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE E4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST;

ADD ON THERAPY; ADRENERGIC SYSTEM; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHODILATATION; BRONCHUS MUCOSA; CORTICOSTEROID THERAPY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; HUMAN; INFLAMMATION; PRACTICE GUIDELINE; RESPIRATORY TRACT DISEASE; REVIEW;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; DRUG THERAPY, COMBINATION; HUMANS; LEUKOTRIENE ANTAGONISTS; TREATMENT OUTCOME;

EID: 0042324368     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Busse WW. Inflammation in asthma: the cornerstone of the disease and target of therapy. J Allergy Clin Immunol 1998;102(4 Pt 2):S17-22.
2. Sont JK, Willems LN, Bel EH, Krieken JH van, Vandenbroucke JP, Sterk PJ. Clinical control and histopathological outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 1999;159:1043-51.
3. Louis R, Lau LCK, Bron AO, Roldaan AC, Radermecker M, Djukanovic R. The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med 2000;161:9-16.
4. Jeffery PK. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med 2001;164(10 Pt 2):S28-38.
5. Lambert RK, Wiggs BR, Kuwano K, Hogg JC, Pare PD. Functional significance of increased airway smooth muscle in asthma and COPD. J Appl Physiol 1993;74:2771-81.
6. Ward C, Pais M, Bish R, Reid D, Feltis B, Johns D, et al. Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax 2002;57:309-16.
7. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360:1715-21.
8. Geijer RMM, Schayck CP van, Weel C van, Sachs APE, Bottema BJAM, Smeele IJM, et al. NHG-standaard COPD: behandeling. Huisarts Wet 2001;44:207-19.
9. Efthimiou J, Barnes PJ. Effect of inhaled corticosteroids on bones and growth. Eur Respir J 1998;11:1167-77.
10. Dekhuijzen PNR. Asthma bronchiale. Een aandoening van grote én kleine luchtwegen. Pharm Weekbl 2002;137:14-5.
11. Dworski R, Fitzgerald GA, Oates JA, Sheller JR. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med 1994;149(4 Pt 1):953-9.
12. National Institutes of Health (NIH). Global initiative for asthma: global strategy for asthma management and prevention. NIH-publication 02-3659. National Heart, Blood, and Lung Institute/WHO Workshop report. Bethesda, Md.: NIH; 2002.
13. Pauwels RA, Löfdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337:1405-11.
14. Lemanske jr RF, Sorkness CA, Mauger EA, Lazarus SC, Boushey HA, Fahy JV, et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA 2001;285:2594-603.
15. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001;164(8 Pt 1):1392-7.
16. Eickelberg O, Roth M, Lörx R, Bruce V, Rüdiger J, Johnson M, et al. Ligand-independent activation of the glucocorticoid receptor by β2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999;274:1005-10.
17. Bjermer L. History and future perspectives of treating asthma as a systemic and small airways disease. Respir Med 2001;95:703-19.
18. Calhoun WJ, Hinton KL, Kratzenberg JJ. The effect of salmeterol on markers of airway inflammation following segmental allergen challenge. Am J Respir Crit Care Med 2001;163:881-6.
19. Roberts JA, Bradding P, Britten KM, Walls AF, Wilson S, Gratziou C, et al. The long-acting beta2-agonist salmeterol xinafoate: effects on airway inflammation in asthma. Eur Respir J 1999;14:275-82.
20. Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ. Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. Chest 2001;119:1021-6.
21. Edelman JM, Turpin JA, Bronsky EA, Grossman J, Kemp JP, Ghannam AF, et al. Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group. Ann Intern Med 2000;132:97-104.
22. Newnham DM, DcDevitt DG, Lipworth BJ. Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma. Am J Med 1994;97:29-37.
23. Grove A, Lipworth BJ. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet 1995;346: 201-6.
24. Sampson AP, Pizzichini E, Bisgaard H. Effect of cysteinyl leukotrienes and leukotriene receptor antagonists on markers of inflammation. J Allergy Clin Immunol 2003;111:S49-59.
25. Howarth PH. Leukotrienes in rhinitis. Am J Respir Crit Care Med 2000;161(2 Pt 2):S133-6.
26. Fauler J, Neumann Ch, Tsikas D, Frolich J. Enhanced synthesis of cysteinyl leukotrienes in atopic dermatitis. Br J Dermatol 1993; 128:627-30.
27. Panettieri RA, Tan EML, Ciocca V, Luttmann MA, Leonard TB, Hay DW. Effects of LTD4 on human airway smooth muscle cell proliferation, matrix expression, and contraction in vitro: differential sensitivity to cysteinyl leukotriene receptor antagonists. Am J Respir Cell Mol Biol 1998;19:453-61.
28. Figueroa DJ, Breyer RM, Defoe SK, Kargman S, Daugherty BL, Waldburger K, et al. Expression of the cysteinyl leukotriene 1 receptor in normal human lung and peripheral blood leukocytes. Am J Respir Crit Care Med 2001;163:226-33.
29. Diamant Z, Sterk PJ. Nieuwe therapie van asthma bronchiale: toepassing van leukotrieenreceptorantagonisten en leukotrieensyntheseremmers. Ned Tijdschr Geneeskd 1998;142:72-8.
30. Diamant Z, Sampson AP. Anti-inflammatory mechanisms of leukotriene modulators. Clin Exp Allergy 1999;29:1449-53.
31. Wilson AM, Orr LC, Sims EJ, Dempsey OJ, Lipworth BJ. Antiasthmatic effects of mediator blockade versus topical corticosteroids in allergic rhinitis and asthma. Am J Respir Crit Care Med 2000;162(4 Pt 1):1297-301.
32. Laviolette M, Malmstrom K, Lu S, Chervinsky P, Pujet JC, Peszek I, et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med 1999;160:1862-8.
33. Simons FE, Villa JR, Lee BW, Teper AM, Lyttle B, Aristizabal G, et al. Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study. J Pediatr 2001; 138:694-8.
34. Lofdahl CG, Reiss TF, Leff JA, Israel E, Noonam MJ, Finn AF, et al. Randomised, placebo-controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999;319:87-90.
35. Robinson DS, Campbell D, Barnes PJ. Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial. Lancet 2001;357:2001-11.
36. Christian Virchow J, Prasse A, Naya I, Summerton L, Harris A. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med 2000;162 (2 Pt 1):578-85.
37. Price DB, Hernandez D, Magyar P, Fiterman J, Beeh KM, James IG, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Clinical Outcomes with Montelukast as a Partner Agent to Corticosteroid Therapy (COMPACT) International Study Group. Thorax 2003;58:211-6.
38. Price DB, Rouleau MY, Fletcher CP, Patel P, Olivenstein R, Myhr L, et al. Use of montelukast in tapering inhaled corticosteroid therapy: an open-label 48-week trial. Curr Ther Res 2001;62:743-55.
39. Green RH, Pavord ID. Leukotriene antagonists and symptom control in chronic persistent asthma. Lancet 2001;357:1991-2.
40. Fish JE, Israel E, Murray JJ, Emmett A, Boone R, Yancey SW, et al. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest 2001;120:423-30.
41. Nelson HS, Busse WW, Kerwin E, Church N, Emmett A, Rickard K, et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2000;106:1088-95.
42. Bjermer L, Bisgaard H, Bousquet J, Fabbri LM, Greening A, Haahtela T, et al. Montelukast or salmeterol combined with an inhaled steroid in adult asthma: design and rationale of a randomized, double-blind comparative study (the IMPACT Investigation of Montelukast as a Partner Agent for Complementary Therapy-trial). Respir Med 2000;94:612-21.
43. Bjermer L, Diamant Z. The use of leukotriene receptor antagonists (LTRAs) as complementary therapy in asthma. Monaldi Arch Chest Dis 2002;57:76-83.